Sardu Celestino, Marfella Raffaele, Testa Gianluca, Santamaria Matteo, Sacra Cosimo, Ranauro Alfredo, Paolisso Giuseppe, Rizzo Maria Rosaria, Barbieri Michelangela
Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania "Luigi Vanvitelli", Naples Department of Medicine and Health Sciences, University of Molise Cardiovascular and Arrhythmias Department, John Paul II Research and Care Foundation, Campobasso, Italy.
Medicine (Baltimore). 2018 Aug;97(31):e11757. doi: 10.1097/MD.0000000000011757.
The aim of this study was to investigate syncope recurrence in patients with a 2A cardioinhibitory response to the head up tilt testing (HUT).
In this study, we enrolled 72 consecutive patients affected by syncope with cardioinhibitory response without asystolic significant pause to HUT (2A type). In these patients, we randomly performed electrophysiological study (ES). In case of sino-atrial node, atrio-ventricular node dysfunction, and sustained arrhythmias induction, the ES resulted positive. ES was positive in 9 patients (group A), then treated by catheter ablation, and/or by devices implants. Otherwise, ES resulted negative (group B), and these patients did not receive an interventional treatment. However, after ES, we evaluated syncope recurrence during 360 days follow-up.
There was a lower statistical significant syncope recurrence at follow-up, comparing group A to group B of patients [n of events 9 (40.9%) vs 8 (57.1%), P < .05]. At multivariate analysis, ES result was the only factor predicting syncope recurrence at follow-up (hazard ratio = 27.63, 95% confidence interval = 1.02-54.24, P < .005).
The positivity to ES study, and successful interventional therapies may reduce the burden of syncope recurrence at 360 days follow-up in 2A HUT subjects.Clinical trial number: NCT02861274.
本研究旨在调查对直立倾斜试验(HUT)有2A型心脏抑制反应的患者晕厥复发情况。
在本研究中,我们连续纳入了72例因晕厥且对HUT有心脏抑制反应且无心脏停搏显著间歇的患者(2A型)。在这些患者中,我们随机进行电生理研究(ES)。如果窦房结、房室结功能障碍以及诱发持续性心律失常,则ES结果为阳性。9例患者(A组)的ES结果为阳性,随后接受导管消融和/或植入装置治疗。否则,ES结果为阴性(B组),这些患者未接受介入治疗。然而,在ES后,我们评估了360天随访期间的晕厥复发情况。
随访时,A组患者的晕厥复发率低于B组患者[事件数9例(40.9%)对8例(57.1%),P<0.05]。多因素分析显示,ES结果是预测随访期间晕厥复发的唯一因素(风险比=27.63,95%置信区间=1.02-54.24,P<0.005)。
ES研究阳性及成功的介入治疗可能会减轻2A型HUT受试者360天随访时晕厥复发的负担。临床试验编号:NCT02861274。